Biography
Blake Wise is Chief Executive Officer at Novome Biotechnologies, a biotechnology company focused on developing engineered cellular therapies for the gut to treat chronic diseases. Prior to Novome, Mr. Wise served as Chief Executive Officer of Achaogen where he oversaw the development and FDA approval of ZEMDRI (plazomicin) for adults with complicated urinary tract infections. Prior to joining Achaogen, Mr. Wise spent 13 years at Genentech in multiple leadership positions of increasing responsibility, including Vice President in Genentech’s BioOncology business unit. Prior to joining Genentech, Mr. Wise worked in consumer marketing, e-commerce and online marketing in leadership positions at Gap, Inc. and Webvan. Mr. Wise received a Bachelor of Arts degree in Business Economics from University of California, Santa Barbara, and a Masters of Business Administration degree from University of California, Berkeley, Haas School of Business.

Emerging Therapeutics Showcase:
Novome Biotechnologies
Novome Biotechnologies is a clinical stage biotechnology company developing engineered cellular therapies for the gut to treat chronic diseases.

Engineering Living Medicines for Chronic Diseases
In this talk, we discuss Novome’s novel foundational technology for controllably colonizing the gut with therapeutically engineered cells, our broad pipeline, and clinical results from a Phase 1 healthy volunteer study of our lead program, NOV-001.